Literature DB >> 22207531

Risk factors for laryngopharyngeal reflux.

Murat Saruç1, Elif Ayanoglu Aksoy, Eser Vardereli, Mehmet Karaaslan, Bahattin Ciçek, Umit Ince, Ferhan Oz, Nurdan Tözün.   

Abstract

The aim of this study was to evaluate the demographic and clinicopathologic characteristics of gastroesophageal reflux disease (GERD) with and without laryngopharyngeal reflux (LPR) to determine the risk factors for the occurrence of LPR in patients with GERD. This is a retrospective study of GERD patients with and without LPR. From the outpatient computer program of our hospital we randomly enrolled 45 GERD patients with LPR into the first group and another 45 GERD patients without LPR to the second group. Medical records of the patients in both groups were examined. All patients underwent upper gastrointestinal system endoscopy. LPR was confirmed by laryngoscopy, and LPR-related laryngoscopy scoring. Non-erosive GERD (NERD), erosive GERD (ERD) and Barrett's esophagus (BE) were diagnosed by endoscopy and histopathology. Various clinical parameters including status of Helicobacter pylori (H. pylori) infection, topography of gastritis were analyzed. For therapy, lansoprazole in a dosage of 30 mg BID for at least 8 weeks were given to all patients in both groups. GERD patients with and without LPR were compared according to demographic, clinic, endoscopic and histopathological parameters. The results revealed that patients with LPR were younger than the patients without LPR (38.7 ± 10.2 years and 43.8 ± 11.5 years; p = 0.08); however, there was no statistical significance. Patients without LPR showed no gender predilection (55% male) while LPR patients showed male preponderance (71% male). In LPR group, 11 patients (24%) had NERD, while 28 (62%) and 6 (13%) patients had ERD and BE, respectively. Twenty-seven (60%) patients without LPR were diagnosed as NERD, 15 patients (33%) without LPR had ERD and only 3 patients (6.6%) showed the histological findings of BE. The patients in LPR group had higher body mass index. Hiatal hernia was more frequent in the patients with LPR (53%) than in the patients without LPR (24%) (p = 0.005). LPR patients had longer duration of reflux symptoms than the patients without LPR (p = 0.04). H. pylori status was not different in both groups but the patients without LPR had more corpus gastritis than the patients with LPR. Eight weeks of lansoprazole treatment was successful in 71% of patients with LPR, and 86% of patients without LPR. We concluded that male gender, hiatal hernia, longer duration of symptoms, high BMI, having ERD and BE seems as risk factors for the occurrence of LPR in patients with GERD. H. pylori status did not have any effect on the development of LPR. Corpus dominant gastritis may have a protective role against the development of LPR. Proton pump inhibitor therapy is less effective in patients with LPR.

Entities:  

Mesh:

Year:  2011        PMID: 22207531     DOI: 10.1007/s00405-011-1905-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  27 in total

Review 1.  Supraesophageal complications of reflux disease and hiatal hernia.

Authors:  P J Kahrilas
Journal:  Am J Med       Date:  2001-12-03       Impact factor: 4.965

2.  Patients with isolated laryngopharyngeal reflux are not obese.

Authors:  Stacey L Halum; Gregory N Postma; Crawford Johnston; Peter C Belafsky; Jamie A Koufman
Journal:  Laryngoscope       Date:  2005-06       Impact factor: 3.325

Review 3.  ENT manifestations of gastroesophageal reflux.

Authors:  R K Wong; D G Hanson; P J Waring; G Shaw
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

4.  The validity and reliability of the reflux finding score (RFS).

Authors:  P C Belafsky; G N Postma; J A Koufman
Journal:  Laryngoscope       Date:  2001-08       Impact factor: 3.325

5.  Is pseudosulcus alone a reliable sign of gastroesophago-pharyngeal reflux?

Authors:  R Ylitalo; P-A Lindestad; S Hertegard
Journal:  Clin Otolaryngol Allied Sci       Date:  2004-02

6.  Hoarseness and misdirected swallowing in patients with hiatal hernia.

Authors:  Anna-Britta Mjönes; Kurt Borch; Lita Tibbling; Torbjörn Ledin; Elisabeth Hultcrantz
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-21       Impact factor: 2.503

7.  Validity and reliability of the reflux symptom index (RSI).

Authors:  Peter C Belafsky; Gregory N Postma; James A Koufman
Journal:  J Voice       Date:  2002-06       Impact factor: 2.009

8.  Should patients with pH-documented laryngopharyngeal reflux routinely undergo oesophagogastroduodenoscopy? A retrospective analysis.

Authors:  O Reichel; W J Issing
Journal:  J Laryngol Otol       Date:  2007-10-12       Impact factor: 1.469

9.  Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.

Authors:  Kevin M Reavis; Cynthia D Morris; Deepak V Gopal; John G Hunter; Blair A Jobe
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

10.  Manifestations of gastro-pharyngo-laryngeal reflux disease.

Authors:  F Mosca; V Rossillo; C A Leone
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-10       Impact factor: 2.124

View more
  7 in total

1.  The effects of Helicobacter pylori eradication therapy on salivary pepsin concentration in patients with laryngopharyngeal reflux.

Authors:  Qing-Qing Zhang; Meng Xie; Rui-Xin Guo; Xiao-Hong Liu; Si-Jing Ma; Yang-Juan Chen; Min-Juan Yang; Ye-Wen Shi; Xiao-Yong Ren; Hua-Nan Luo
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-08       Impact factor: 3.236

2.  Gastric reflux is an independent risk factor for laryngopharyngeal carcinoma.

Authors:  Scott M Langevin; Dominique S Michaud; Carmen J Marsit; Heather H Nelson; Ariel E Birnbaum; Melissa Eliot; Brock C Christensen; Michael D McClean; Karl T Kelsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-23       Impact factor: 4.254

3.  Higher levels of total pepsin and bile acids in the saliva as a possible risk factor for early laryngeal cancer.

Authors:  Maja Sereg-Bahar; Ales Jerin; Irena Hocevar-Boltezar
Journal:  Radiol Oncol       Date:  2015-03-03       Impact factor: 2.991

4.  Laryngopharyngeal reflux disease in the Greek general population, prevalence and risk factors.

Authors:  Nikolaos Spantideas; Eirini Drosou; Anastasia Bougea; Dimitrios Assimakopoulos
Journal:  BMC Ear Nose Throat Disord       Date:  2015-12-21

5.  Nissen fundoplication vs proton pump inhibitors for laryngopharyngeal reflux based on pH-monitoring and symptom-scale.

Authors:  Chao Zhang; Zhi-Wei Hu; Chao Yan; Qiong Wu; Ji-Min Wu; Xing Du; Dian-Gang Liu; Tao Luo; Fei Li; Zhong-Gao Wang
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

6.  Laryngopharyngeal reflux disease, prevalence and clinical characteristics in ENT department of a tertiary hospital Tanzania.

Authors:  Willybroad A Massawe; Aslam Nkya; Zefania Saitabau Abraham; Kassim M Babu; Ndeserua Moshi; Aveline A Kahinga; Daudi Ntunaguzi; Enica R Massawe
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-08-26

7.  Awareness about laryngopharyngeal reflux disease among Chinese otolaryngologists: a nationwide survey.

Authors:  Shuifang Xiao; Jinrang Li; Hongliang Zheng; Xiangping Li; Hui Yang; Junbo Zhang; Xiaoxia Peng; Shuihong Zhou; Chen Zhao; Donghui Chen; Xuping Xiao; Li Shi; Hui Huangfu; Zhenfeng Tao; Xiong Chen; Yehai Liu; Shenhong Qu; Guangke Wang; Ting Chen; Xiaobo Cui; Linli Tian; Wensheng Zhou; Hongyan Fang; Yongwang Huang; Guodong Yu; Zhenqun Lin; Liang Tang; Jian He; Ruixia Ma; Zhaoyan Yu
Journal:  BMJ Open       Date:  2022-06-22       Impact factor: 3.006

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.